GSK to Sell Stake in Haleon Valued at About $1.61 Billion
By David Sachs
GSK said it will sell its remaining stake in Haleon, ending its gradual disposal of shares in the company.
The British pharmaceutical company said Thursday that it plans to sell about 385 million ordinary shares in the London-listed consumer healthcare company, or about 4.2% of Haleon's share capital. The shares are valued at about GBP1.27 billion ($1.61 billion), based on Haleon's current market capitalization.
The price will be determined by an accelerated bookbuilding offering process that will start immediately, GSK said.
Haleon was formed in 2019 via the merger of GSK and pharmaceutical giant Pfizer's consumer-healthcare businesses into a new joint-venture, before being spun out and listed on the London Stock Exchange in 2022.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 16, 2024 12:28 ET (16:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates